Bristol Myers Squibb Company $BMY Position Lifted by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. raised its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.6% in the third quarter, Holdings Channel.com reports. The fund owned 274,249 shares of the biopharmaceutical company’s stock after buying an additional 19,441 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Bristol Myers Squibb were worth $17,113,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BMY. Verdence Capital Advisors LLC increased its position in Bristol Myers Squibb by 17.7% during the 3rd quarter. Verdence Capital Advisors LLC now owns 24,309 shares of the biopharmaceutical company’s stock worth $1,517,000 after purchasing an additional 3,647 shares in the last quarter. Flagship Harbor Advisors LLC lifted its position in Bristol Myers Squibb by 2.3% during the third quarter. Flagship Harbor Advisors LLC now owns 30,167 shares of the biopharmaceutical company’s stock valued at $1,882,000 after buying an additional 675 shares in the last quarter. apricus wealth LLC acquired a new position in Bristol Myers Squibb during the third quarter valued at approximately $217,000. Westover Capital Advisors LLC grew its stake in Bristol Myers Squibb by 59.8% during the third quarter. Westover Capital Advisors LLC now owns 6,682 shares of the biopharmaceutical company’s stock worth $417,000 after buying an additional 2,500 shares during the period. Finally, Leo Wealth LLC purchased a new stake in Bristol Myers Squibb during the third quarter worth approximately $2,445,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $61.56 on Tuesday. The company has a market capitalization of $125.75 billion, a PE ratio of 13.56, a price-to-earnings-growth ratio of 0.31 and a beta of 0.19. The firm has a fifty day simple moving average of $63.20 and a 200-day simple moving average of $59.79. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same period last year, the business earned $1.46 EPS. The business’s revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.51 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Promising lung-cancer results: Iza-bren doubled median progression-free survival versus chemotherapy in previously treated EGFR-mutated non-small-cell lung cancer in the Phase 3 PANKU-Lung01 study. The results strengthen the potential of BMY’s pipeline to offset declining legacy-drug revenue. Iza-bren lung-cancer Phase 3 results
• Positive Sentiment: Additional oncology momentum: A Phase 3 breast-cancer study reportedly showed Iza-bren reduced disease-progression risk by as much as 38%, while a Phase 2 trial of BMY and BioNTech’s pumitamig plus docetaxel produced a 36.7% response rate in advanced non-small-cell lung cancer. These programs could broaden BMY’s growth-drug portfolio. BMY cancer breakthrough Pumitamig Phase 2 data
• Positive Sentiment: Analyst remains bullish: Piper Sandler maintained an “overweight” rating and still sees substantial potential upside, despite reducing its price target from $82 to $78. Piper Sandler BMY rating
• Neutral Sentiment: Q3 earnings focus: Investors are weighing growth from newer medicines and improved Eliquis guidance against declines in BMY’s legacy portfolio ahead of quarterly results. Analysts are also monitoring revenue, margins and other operating metrics. BMY Q3 earnings outlook
• Negative Sentiment: Patent-cliff risk persists: Investors remain concerned that patent expirations for two blockbuster drugs could create a significant revenue gap before new medicines fully mature, despite BMY’s low valuation and dividend appeal. BMY patent-cliff analysis
• Negative Sentiment: Cautious earnings sentiment: Erste Group issued a pessimistic earnings outlook, adding to broader sell-side caution around BMY’s growth rate and post-patent-cliff prospects.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BMY. Morgan Stanley reissued an “underweight” rating and issued a $41.00 target price (up from $40.00) on shares of Bristol Myers Squibb in a research note on Wednesday, October 7th. Piper Sandler lowered their price target on Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating for the company in a report on Monday. Daiwa Securities Group raised their price objective on Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. HSBC restated a “hold” rating and set a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a research note on Thursday, September 10th. Finally, Zacks Research downgraded Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 22nd. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $65.50.

About Bristol Myers Squibb

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.